Jan 1 |
et al., NCT06511063 | Investigating the Feasibility of Repurposing HIV Antivirals in Adults With Long Covid |
| Estimated 90 patient Tenofovir late treatment RCT with results not reported over 10 months after estimated completion. | ||
Oct 17 2024 |
et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-024-00781-3 | Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial |
| 89% lower ventilation (p=0.11). RCT 60 hospitalized COVID-19 patients showing fewer mechanical ventilation and ICU days with tenofovir alafenamide fumarate (TAF) treatment in addition to remdesivir and corticosteroids. | ||
Aug 20 2022 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac628 | Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial |
| 76% higher mortality (p=0.38) and 6% lower progression (p=0.77). RCT 355 high-risk, mostly hospitalized COVID-19 patients showing no significant benefit with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) treatment. | ||
Aug 5 2022 |
et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006 | Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers |
| 66% fewer symptomatic cases (p=0.59) and 19% fewer cases (p=0.51). Early terminated healthcare worker prophylaxis RCT in Spain, showing lower risk of symptomatic cases with both HCQ and tenofovir disoproxil fumarate/emtricitabine, without statistical significance due to the small number of events. | ||
Dec 31 2021 |
et al., European Journal of Respiratory Medicine, doi:10.31488/EJRM.122 | Clinical Features, Pathobiology, Efficacy, and Toxicity of Tenofovir Disoproxil Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections |
| 80% lower hospitalization (p=0.24) and 9% worse recovery (p=0.82). RCT 226 outpatients showing no significant difference with tenofovir disoproxil fumarate (TDF) alone or combined with emtricitabine (FTC) for mild to moderate COVID-19, compared with vitamin C. | ||
Aug 31 2021 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.100993 | Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial |
| 11% improved recovery (p=0.47) and 37% improved viral clearance (p=0.1). RCT 60 outpatients with mild/moderate COVID-19 showing no significant clinical benefit with tenofovir disoproxil fumarate plus emtricitabine. The primary endpoint of viral load reduction at day 4 was not met (p=0.13), though a secondary e.. | ||
Jul 10 2021 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101242 | Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial |
| 32% lower mortality (p=0.19). RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, 160 treated with emtricitabine + tenofovir, and 159 treated with the combination of both regimens. Statistically significant improvement was seen only .. | ||
Apr 1 2021 |
et al., NCT04519125 | Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial |
| Estimated 950 participant Tenofovir prophylaxis RCT with results not reported over 5 years after estimated completion. | ||
Nov 15 2020 |
et al., NCT04405271 | Randomized, Double-blind, Placebo-controlled Trial of TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) |
| 1,378 participant Tenofovir prophylaxis RCT with results not reported over 5 years after completion. | ||